Xeljanz 5 MG tablet UU 60S
Ended Awarded
- Contract number
- SPE2DR26FY8EK
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,731
Award facts
- Contract value 100% obligated
- $12,731.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,731.42 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) under a firm fixed price contract. The award, issued on November 14, 2025, with an ultimate completion date of November 17, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location. This contract is a child delivery order issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026.
The Xeljanz procurement supports the federal military healthcare supply chain, enabling the Defense Health Agency and related military medical facilities to access this immunosuppressive medication used in the treatment of rheumatoid arthritis and other autoimmune conditions. AmerisourceBergen Drug Corp's SPE2DX prime vendor contract serves as a comprehensive global pharmaceutical support vehicle, allowing the company to deliver brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The DLA's strategic approach includes plans for the Pharmaceutical Prime Vendor Global Program Generation V contracts, with intentions to make multiple regional awards, positioning AmerisourceBergen Drug Corp as a critical pharmaceutical distributor within the federal medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FY8EK?
SPE2DR26FY8EK was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 14, 2025.
How much is contract SPE2DR26FY8EK worth?
The government has obligated $12,731 on SPE2DR26FY8EK.
Is contract SPE2DR26FY8EK an order under another contract?
Yes. SPE2DR26FY8EK is a delivery order under SPE2DR25D1007, an indefinite delivery contract.
Was contract SPE2DR26FY8EK competed?
The extent of competition for SPE2DR26FY8EK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award